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ABSTRACT
The aim of this case report is to present the 
life saving use of extracorporeal membrane 
oxygenation (ECMO) in an obstetric pa-
tient with acute cardiorespiratory collapse 
following massive bleeding caused by an 
atonic uterus post partum. A 39-year-old 
patient, following a spontaneous abor-
tion at 21 weeks of pregnancy, developed 
uterine atony and massive bleeding and 
was ultimately referred to the operating 
room for an emergent hysterectomy. Post-
operatively, she was referred to the inten-
sive care unit (ICU) where she developed 
severe acute respiratory distress syndrome 
(ARDS) that was successfully treated by 
employing ECMO. Following discontinu-
ation of ECMO, her treatment was further 
complicated by a manifest hemolytic trans-
fusion reaction. Although extensive testing 
was done to establish the cause of this reac-
tion, we were unable to find it. The patient 
responded well to treatment with erythro-
poietin (EPO) and corticosteroids as well 
as a restrictive transfusion regime. This 
treatment pointed to a possible immune 
reaction to massive transfusions of blood 
products. This case demonstrated the im-
portance of early aggressive treatment us-
ing ECMO in reversal of life threatening 
ARDS, as well as the need for a judicious 
approach when transfusing blood prod-
ucts.
Key words: ECMO (extracorporeal mem-
brane oxygenation), hemorrhagic diathesis, 
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INTRODUCTION
The treatment of patients with cardiores-
piratory failure frequently requires the use 
of extracorporeal membrane oxygenation 
(ECMO). There have been clear demon-
strations of its benefit in the general popu-
lation of patients, with various indications. 
(1)
Successful use of ECMO immediately 
postpartum has been reported in several 
case studies in obstetric patients with vari-
ous indications. (2-8)
In this report, we present a complex case 
of an obstetric patient with massive hem-
orrhage after a spontaneous abortion at 21 
weeks of gestation. There was implemen-
tation of ECMO, as a life saving measure, 
which allowed the recovery of the patient’s 
cardiorespiratory functions.
CASE PRESENTATION
A 39-year-old female patient, at 21 weeks 
of gestation of a previously uncomplicated 
pregnancy, was referred to the delivery 
room due to suspected leakage of amniotic 
fluid. The first ultrasound exam revealed 
a healthy live female fetus with biometry 
corresponding to 21 weeks of gestation. 
Contractions appeared, amniotic mem-
branes ruptured spontaneously, and five 
hours later, a dead fetus weighing 480 g 
was miscarried. Placental and decidual 
tissues were removed instrumentally dur-
ing short intravenous anesthesia. Massive 
vaginal bleeding and hemodynamic insta-
bility complicated the early postpartum 
period; therefore, the patient was subjected 
to repeated curettage to establish control of 
bleeding. Bleeding continued, until finally, 
the patient underwent emergent transab-
dominal hysterectomy.
Preoperatively drawn coagulation tests 
showed the development of severe coagu-
lopathy (DIC). The attending anesthesiolo-
gist instituted a massive transfusion proto-
col. Intraoperatively, the patient received 
3480 mL of packed red blood cells, 2040 
mL of freshly frozen plasma (FFP), and 
700 mL of packed thrombocytes using a 
rapid infusion system. Despite attempts at 
hemodynamic stabilization, which besides 
blood and volume replacement also in-
cluded a continuous infusion of vasoactive 
drugs, the patient went into short cardiac 
arrest twice during the operation and was 
successfully resuscitated on both occa-
sions. The patient also developed signs of 
acute respiratory distress (ARDS), mani-
fested by extreme difficulty at maintaining 
mechanical ventilation and massive alveo-
lar discharge.
She was admitted to the intensive care unit 
(ICU) postoperatively, where hemody-
namic and respiratory instability contin-
ued. Hypoxemia developed (PaO2/FiO2 
ratio of 67 on day two with FiO2>80%) 
despite aggressive mechanical respiratory 
support, and therefore, ECMO (Maquet 
Cardiohelp; Hirlingen, Germany) was in-
dicated. In addition, due to developing 
acute renal failure, continuous vena-ve-
nous hemodialysis (CVVHD) ((Gambro 
Lundia; Lund, Sweden) was also needed. 
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Throughout the early period, continu-
ing coagulopathy and manifest bleeding 
further complicated treatment, because 
of which, massive transfusions were still 
needed.
During the 8 days of ECMO treatment, 
the patient achieved adequate respiratory 
parameters and the system was decannu-
lated. ECMO clinical course is displayed 
in table 1. After 15 days of treatment, renal 
function recovered and CVVHD was dis-
continued.
Sedation was discontinued at day 18 and 
the patient slowly regained consciousness 
during the next few days. She fully awoke 
and was extubated on day 29 of treatment.
However, from day 13 of treatment, we ob-
served an increased level of hemolysis and 
an increase in serum bilirubin levels. This 
trend continued throughout the following 
weeks. Direct Coombs tests, performed on 
several occasions, confirmed the presence 
of agglutinated antibodies on the surface of 
erythrocytes. Further diagnostic tests were 
unable to establish the target of antibody 
agglutination. Tests done to establish the 
presence of circulating irregular antibod-
ies were negative on multiple occasions. 
Following consultations with a hematolo-
gist, we attempted plasmapheresis several 
times. This proved unsuccessful in treat-
ing the hemolytic reaction, and on day 33, 
corticosteroid treatment and application 
of erythropoietin (EPO) commenced. We 
also started treatment with Folacin and 
iron supplements and implemented a re-
strictive regimen of transfusion therapy. 
Ultimately, these treatments proved suc-
cessful, and on day 40, we observed a drop 
in the rate of hemolysis and serum biliru-
bin levels for the first time. During the re-
maining 11 days of treatment, the rate of 
hemolysis, hemoglobin, and hematocrit 
values slowly normalized.
The patient also underwent several surgi-
cal procedures during her ECMO treat-
ment to achieve control of bleeding and 
evacuate hematomas. These are listed in 
table 2.
Finally, on day 55 of treatment, we released 
the patient to a medical team for air trans-
port to her homeland.
Table 1. Clinical ECMO course.
Day of ICU 
treatment
Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9
Day of ECMO 
treatment
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8
pH 7.17 7.47 7.45 7.39 7.55 7.50 7.50 7.47
pCO2 (kPa) 5.7 3.9 4.9 5.6 3.6 3.1 4.8 4.9
pO2 (kPa) 7.2 11.9 10.0 8.9 11.4 13.1 15.9 19.4
SO2 (%) 79.2 97.4 95.7 93 97.6 98.0 98.6 99.0
Hb (g/L) 59 81 74 115 90 84 74 84
Htc 0.15 0.25 0.22 0.34 0.26 0.23 0.22 0.25
O2 (l/min) – 
oxy
3.6 4.9 5.2 5.2 5.3 5.4 5.3 5.3
FiO2 – oxy 0.75 0.84 0.84 0.82 0.85 0.86 0.88 0.88
RPM 2200 2595 2715 2700 2700 2700 2380 2454
LPM 3000 3540 3590 3500 3600 3570 3000 3160
ACT 258 155 166 134 153 145 134 149




11 14 3 0 0 3 10 0
RBC (units, 
whole day)
13 12 6 0 3 8 14 4
Platelets (units, 
whole day)
3 2 2 1 1 2 5 3
ACT, activated clotting time; FFP, Freshly Frozen Plasma units transfused; Hb, Hemoglobin; Htc, Hematocrit; LPM, litres per minute; 
RBC, Red Blood Cells units transfused; RPM, revolutions per minute; oxy, oxygenator.
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Table 2. Surgical interventions.
Day of treatment Type of intervention
Day 2 Chest drainage
Day 2 ECMO Cannulation
Day 2 Emergent decompressive laparotomy
Day 3 Relaparotomy, evacuation of intraabdominal hematoma, tamponade
Day 5 Relaparotomy, drainage and lavage, retamponade
Day 7 Evacuation of intraabdominal hematoma, retamponade
Day 8 Evacuation of intraabdominal hematoma, retamponade
Day 9 ECMO decannulaton
Day 10 Peritoneal lavage and drainage
Day 12 Peritoneal lavage and drainage
Day 14 Peritoneal lavage and drainage
Day 16 Peritoneal lavage and drainage, abdominal wall reconstruction
Day 32 Cystoscopy
Day 34 Relaparotomy, drainage and lavage, evacuation of intraabdominal 
hematoma
Day 40 Relaparotomy, drainage and lavage, evacuation of intraabdominal 
hematoma
DISCUSSION
Postpartum hemorrhage is one of the lead-
ing causes of maternal mortality. Accord-
ing to World Health Organization (WHO) 
statistics, severe bleeding accounts for 27% 
of all deaths in the postpartum period. (9)
Use of ECMO in obstetric patients has 
been described before in cases such as 
ARDS, (2) transfusion related acute lung 
injury (TRALI) following transfusion, (4) 
amniotic fluid embolism, (3) cardiomyo-
pathy, (5) and for management of cardi-
orespiratory collapse following massive 
bleeding. (6,7)
In this case, we reached the decision to 
commence treatment with ECMO very 
early in the course of treatment, primar-
ily due to severe ARDS. We presumed that 
cardiac failure and ARDS in this case were 
the results of hypovolemic shock and sub-
sequent massive volume resuscitation.
Commencing ECMO in a patient with 
impaired coagulation is linked with risks 
in worsening the hemorrhagic diathesis. 
However, according to Extracorporeal Life 
Support Organization Guidelines, only ac-
tive intracranial hemorrhage is considered 
to be a contraindication to ECMO. (10)
Because of the patient’s severe condition, 
and keeping in mind all potential risks in-
volved, we attempted ECMO as a life-sav-
ing measure. Lamb et al. have shown that 
there can be successful management of 
ECMO bleeding complications in patients 
with primary respiratory failure. (8)
According to ECMO guidelines, there 
are no contraindications of surgical pro-
cedures during treatment; in fact, early 
aggressive treatment targeting potential 
causes of cardiorespiratory collapse are en-
couraged. (10)
Bleeding complications in our patient 
continued throughout and this resulted 
in continued massive transfusions during 
early stages of ECMO. CVVHD augment-
ed ECMO treatment due to manifest acute 
renal failure.
Further treatment, following cardiorespi-
ratory stabilization and recovery of renal 
function, was complicated by a hemolytic 
reaction. Initially, we assumed this was 
due to the extensive volume of extracor-
poreal circulation involved; however, the 
trend continued and in fact worsened af-
ter discontinuation of extracorporeal sup-
port. Later, we assumed this was a result 
of an immune reaction to large volumes 
of blood products transfused throughout 
treatment. Direct Coombs test done on 
day 10 of treatment seemed to confirm 
this, as agglutinated antibodies were found 
on the surface of red blood cells (RBCs). 
However, further immunologic testing 
failed to prove the existence of circulating 
antibodies, i.e., , we were unable to find 
the target of this immune reaction. This 
possibly explains why our attempted treat-
ment with plasmapheresis was unsuccess-
ful. However, despite this, the most likely 
explanation for the continued hemolytic 
reaction continued to be an immune re-
sponse of our patient’s body to transfused 
blood products.
Because of this assumed mechanism, we 
decided to commence treatment with EPO 
to stimulate erythropoiesis, together with 
a restrictive regime of blood transfusion, 
which allowed for lower levels of hemo-
globin and hematocrit before transfusing 
RBCs. Corticosteroid therapy was also 
started due to this assumed immunologic 
mechanism. The patient responded well to 
these treatments and fully recovered.
CONCLUSION
Despite potential misgivings of commenc-
ing ECMO in an actively bleeding patient 
with impaired coagulation, our case clearly 
demonstrates that this method has a place 
in the treatment of acute cardiorespiratory 
failure. This case has also shown that, when 
indicated, surgical procedures should be 
done in such a patient. The treating phy-
sicians should always be watchful for pos-
sible bleeding complications, and weigh 
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the potential risks and benefits before 
commencing ECMO, as well as any other 
treatment.
This case also clearly shows the need for 
a judicious approach when transfusing 
blood products in such patients.
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